Efficacy and safety observations of early ivabradine in the treatment of acute decompensated heart failure
Objective To observe the effectiveness and safety of early ivabradine in the treatment of acute decompensated heart failure.Methods From June 2020 to June 2022,100 hospitalized patients over 18 years old for acute decompensated heart failure were included as the subjects,who were divided into a control group(standardized treatment for heart failure)and an experimental group(standardized treatment for heart failure+standardized treatment with early administration of ivavabradine).The mortality,incidence of adverse cardiovascular events,adverse events,the 6-minute walk distance,Minnesota heart failure quality of life score,resting heart rate,echocardiography(left ventricular remodeling,left ventricular relaxation time,and left ventricular stroke volume)180 days after treatment between the two groups were compared.Results The mortality(0％)180 days after treatment and the incidence of adverse cardiovascular events(6％)were lower than those in the control group(12％and 22％)(P＜0.05),while the 6-minute walk distance and the Minnesota heart failure quality of life score were better than those in the control group.Besides,the resting heart rate in the experimental group was lower than that of the control group,and the left ventricular remodeling index of echocardiography was higher than that of echocardiography in the control group(P＜0.05).The incidence of adverse reactions during the treatment group(12％)and that of adverse reactions in the control group(10％)was not significantly different(P＞0.05).Conclusion Based on standardized treatment of heart failure,the early use of ivavabradine has high effectiveness and safety in patients with acute decompensated heart failure.
NETL
NSTL
万方数据
